Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 8:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cobimetinib Clear all
Completed Phase 2 Interventional Results available

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

NCT03554083
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions
Atezolizumab, Cobimetinib, Tiragolumab, Vemurafenib
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Jacksonville, Florida • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1Phase 2 Interventional

Myeloma-Developing Regimens Using Genomics (MyDRUG)

NCT03732703
View directory record Official record
Conditions
Relapsed Refractory Multiple Myeloma
Interventions
Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT02457793
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
Interventions
Cobimetinib, GDC-0994
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 2 Interventional

Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)

NCT05125471
View directory record Official record
Conditions
Arteriovenous Malformations (Extracranial)
Interventions
Cobimetinib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
2 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jun 7, 2026, 8:57 AM EDT
Terminated Early Phase 1 Interventional

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

NCT02382549
View directory record Official record
Conditions
Melanoma
Interventions
BRAF inhibitor, 6MHP, MEK inhibitor
Drug · Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1 Interventional

Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01988896
View directory record Official record
Conditions
Solid Tumors
Interventions
Atezolizumab, Cobimetinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
11
States / cities
Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

NCT03264066
View directory record Official record
Conditions
Solid Tumors
Interventions
Cobimetinib, Atezolizumab, Atezolizumab Cohort 7
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Kansas City, Kansas • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1 Interventional

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

NCT02876224
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Atezolizumab, Bevacizumab, Cobimetinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Aurora, Colorado • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Jun 7, 2026, 8:57 AM EDT
Active, not recruiting Phase 2 Interventional

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

NCT03224767
View directory record Official record
Conditions
BRAF V600E Mutation Present, Papillary Craniopharyngioma
Interventions
Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
106
States / cities
Birmingham, Alabama • Auburn, California • Berkeley, California + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

Single-agent Cobimetinib for Adults With Histiocytic Disorders

NCT02649972
View directory record Official record
Conditions
Histiocytic Disorders
Interventions
Cobimetinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1 Interventional

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

NCT01986166
View directory record Official record
Conditions
Neoplasms
Interventions
Cobimetinib, MEHD7945A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation

NCT02136524
View directory record Official record
Conditions
Healthy Volunteer
Interventions
cobimetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 7, 2026, 8:57 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

NCT02322814
View directory record Official record
Conditions
Breast Cancer
Interventions
Cobimetinib, Paclitaxel, Placebo, Atezolizumab, Nab-Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
11
States / cities
Jacksonville, Florida • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

NCT02091141
View directory record Official record
Conditions
Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
Interventions
Trastuzumab, Pertuzumab, Erlotinib, Vemurafenib, Cobimetinib, Vismodegib, Alectinib, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
60
States / cities
Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1 Interventional

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

NCT02670044
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Cobimetinib, Idasanutlin, Venetoclax
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

NCT01656642
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Atezolizumab, Cobimetinib, Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Results available

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01562275
View directory record Official record
Conditions
Neoplasms
Interventions
Ipatasertib, Cobimetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2016 · Synced Jun 7, 2026, 8:57 AM EDT
Withdrawn Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

NCT01974258
View directory record Official record
Conditions
Neoplasms
Interventions
Cobimetinib, Onartuzumab, Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Los Angeles, California • Sarasota, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 7, 2026, 8:57 AM EDT
Completed No phase listed Observational

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

NCT05611229
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Nivolumab, Pembrolizumab, Dabrafenib+Trametinib, Ipilimumab+Nivolumab, Vemurafenib+Cobimetinib, Encorafenib+Binimetinib
Drug · Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Jun 7, 2026, 8:57 AM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

NCT03202316
View directory record Official record
Conditions
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Interventions
Atezolizumab, Cobimetinib, Eribulin, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage

NCT02300025
View directory record Official record
Conditions
Healthy Volunteer
Interventions
cobimetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Jun 7, 2026, 8:57 AM EDT
Recruiting Early Phase 1 Interventional

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

NCT04005690
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib, Tremelimumab
Drug · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 7, 2026, 8:57 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

NCT05691504
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cobimetinib, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pelcitoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 7, 2026, 8:57 AM EDT
Completed Phase 1 Interventional Results available

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

NCT01271803
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Cobimetinib, vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Jun 7, 2026, 8:57 AM EDT